Liraglutide: difference between revisions
Diff·revision 22 → 23·07:17, 29 Jul 2025
Difference between revision 22 and revision 23 of Liraglutide. 3 lines changed; the page grew by 152 bytes.
| Revision 22 — 18:12, 4 Jul 2025 SemaglutideSasha (talk) split §Pharmacology into receptor binding and downstream signalling 5,815 bytes +547 | Revision 23 — 07:17, 29 Jul 2025 RetatrutideRuben (talk) give the isoelectric point with the method it was determined by 5,967 bytes +152 | ||
|---|---|---|---|
| 51 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | 51 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> |
| 52 | 52 | ||
| + | 53 | == External links == | |
| + | 54 | * [https://clinicaltrials.gov/study/NCT01179048 LEADER — NCT01179048] — Registry record for the cardiovascular outcome trial. | |
| + | 55 | ||
| 53 | == See also == | 56 | == See also == |
| 54 | * [[GLP-1 receptor agonist]] | 57 | * [[GLP-1 receptor agonist]] |